Radioembolization Super Survivors: Extended Survival in Non-operative Hepatocellular Carcinoma

Andrew C. Gordon, Ahmed Gabr, Ahsun Riaz, Omar M. Uddin, Nadine Abouchaleh, Rehan Ali, Joseph Kallini, Riad Salem, Robert J Lewandowski*

*Corresponding author for this work

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: To identify baseline characteristics and long-term prognostic factors in non-transplant patients with unresectable hepatocellular carcinoma (HCC) who had prolonged survival after treatment with yttrium-90 radioembolization (Y90). Materials and Methods: Sixty-seven “Super Survivors” (defined as ≥ 3-year survival after Y90) were identified within our 1000-patient Y90 database (2003–2017). Baseline imaging and follow-up occurred at 1 month and every 3 months thereafter. Overall survival (OS) was calculated with Kaplan–Meier estimates with log-rank test in subgroups: Child–Pugh (CP) score, distribution of disease, portal vein thrombus (PVT), and technique (segmental vs lobar Y90). Results: Median age 69.5 years (range 45–94 years); 69% male; 60% solitary HCC; 79% unilobar disease; 12% PVT; 10% ascites; Barcelona Clinic Liver Cancer Stage A—54%/B—28%/C—16%/D—2%; CP A—70%/B—28%/C—2%. Longest baseline tumor diameter was 5.4 ± 4.0 cm (mean ± SD). All patients had an imaging response (either partial or complete response). Median OS was 67.5 months (95% CI 55.2–82.5). CP score and main PVT stratified median OS (p = 0.0007 and p = 0.0187, respectively). Beyond 3 years, segmental versus lobar Y90 was associated with improved OS with a median OS of 80.2 versus 46.7 months, respectively (p = 0.0024). Dosing > 200 Gy was not a significant predictor of improved OS. Conclusions: Super Survivors spanning the BCLC staging system maintained durable OS after radioembolization that was stratified by the extent of underlying liver disease. The common variable among all patients was an imaging response. Segmental versus lobar Y90 may have a long-term associated OS benefit.

Original languageEnglish (US)
Pages (from-to)1557-1565
Number of pages9
JournalCardioVascular and Interventional Radiology
Volume41
Issue number10
DOIs
StatePublished - Oct 1 2018

Fingerprint

Survivors
Hepatocellular Carcinoma
Yttrium
Survival
Portal Vein
Thrombosis
Liver Neoplasms
Ascites
Liver Diseases
Databases

Keywords

  • Hepatocellular carcinoma
  • Radioembolization
  • Survival
  • Yttrium-90

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Cite this

Gordon, Andrew C. ; Gabr, Ahmed ; Riaz, Ahsun ; Uddin, Omar M. ; Abouchaleh, Nadine ; Ali, Rehan ; Kallini, Joseph ; Salem, Riad ; Lewandowski, Robert J. / Radioembolization Super Survivors : Extended Survival in Non-operative Hepatocellular Carcinoma. In: CardioVascular and Interventional Radiology. 2018 ; Vol. 41, No. 10. pp. 1557-1565.
@article{70822310eff747adb8cb532e56d805cd,
title = "Radioembolization Super Survivors: Extended Survival in Non-operative Hepatocellular Carcinoma",
abstract = "Purpose: To identify baseline characteristics and long-term prognostic factors in non-transplant patients with unresectable hepatocellular carcinoma (HCC) who had prolonged survival after treatment with yttrium-90 radioembolization (Y90). Materials and Methods: Sixty-seven “Super Survivors” (defined as ≥ 3-year survival after Y90) were identified within our 1000-patient Y90 database (2003–2017). Baseline imaging and follow-up occurred at 1 month and every 3 months thereafter. Overall survival (OS) was calculated with Kaplan–Meier estimates with log-rank test in subgroups: Child–Pugh (CP) score, distribution of disease, portal vein thrombus (PVT), and technique (segmental vs lobar Y90). Results: Median age 69.5 years (range 45–94 years); 69{\%} male; 60{\%} solitary HCC; 79{\%} unilobar disease; 12{\%} PVT; 10{\%} ascites; Barcelona Clinic Liver Cancer Stage A—54{\%}/B—28{\%}/C—16{\%}/D—2{\%}; CP A—70{\%}/B—28{\%}/C—2{\%}. Longest baseline tumor diameter was 5.4 ± 4.0 cm (mean ± SD). All patients had an imaging response (either partial or complete response). Median OS was 67.5 months (95{\%} CI 55.2–82.5). CP score and main PVT stratified median OS (p = 0.0007 and p = 0.0187, respectively). Beyond 3 years, segmental versus lobar Y90 was associated with improved OS with a median OS of 80.2 versus 46.7 months, respectively (p = 0.0024). Dosing > 200 Gy was not a significant predictor of improved OS. Conclusions: Super Survivors spanning the BCLC staging system maintained durable OS after radioembolization that was stratified by the extent of underlying liver disease. The common variable among all patients was an imaging response. Segmental versus lobar Y90 may have a long-term associated OS benefit.",
keywords = "Hepatocellular carcinoma, Radioembolization, Survival, Yttrium-90",
author = "Gordon, {Andrew C.} and Ahmed Gabr and Ahsun Riaz and Uddin, {Omar M.} and Nadine Abouchaleh and Rehan Ali and Joseph Kallini and Riad Salem and Lewandowski, {Robert J}",
year = "2018",
month = "10",
day = "1",
doi = "10.1007/s00270-018-2008-y",
language = "English (US)",
volume = "41",
pages = "1557--1565",
journal = "CardioVascular and Interventional Radiology",
issn = "7415-5101",
publisher = "Springer Verlag",
number = "10",

}

Radioembolization Super Survivors : Extended Survival in Non-operative Hepatocellular Carcinoma. / Gordon, Andrew C.; Gabr, Ahmed; Riaz, Ahsun; Uddin, Omar M.; Abouchaleh, Nadine; Ali, Rehan; Kallini, Joseph; Salem, Riad; Lewandowski, Robert J.

In: CardioVascular and Interventional Radiology, Vol. 41, No. 10, 01.10.2018, p. 1557-1565.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Radioembolization Super Survivors

T2 - Extended Survival in Non-operative Hepatocellular Carcinoma

AU - Gordon, Andrew C.

AU - Gabr, Ahmed

AU - Riaz, Ahsun

AU - Uddin, Omar M.

AU - Abouchaleh, Nadine

AU - Ali, Rehan

AU - Kallini, Joseph

AU - Salem, Riad

AU - Lewandowski, Robert J

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Purpose: To identify baseline characteristics and long-term prognostic factors in non-transplant patients with unresectable hepatocellular carcinoma (HCC) who had prolonged survival after treatment with yttrium-90 radioembolization (Y90). Materials and Methods: Sixty-seven “Super Survivors” (defined as ≥ 3-year survival after Y90) were identified within our 1000-patient Y90 database (2003–2017). Baseline imaging and follow-up occurred at 1 month and every 3 months thereafter. Overall survival (OS) was calculated with Kaplan–Meier estimates with log-rank test in subgroups: Child–Pugh (CP) score, distribution of disease, portal vein thrombus (PVT), and technique (segmental vs lobar Y90). Results: Median age 69.5 years (range 45–94 years); 69% male; 60% solitary HCC; 79% unilobar disease; 12% PVT; 10% ascites; Barcelona Clinic Liver Cancer Stage A—54%/B—28%/C—16%/D—2%; CP A—70%/B—28%/C—2%. Longest baseline tumor diameter was 5.4 ± 4.0 cm (mean ± SD). All patients had an imaging response (either partial or complete response). Median OS was 67.5 months (95% CI 55.2–82.5). CP score and main PVT stratified median OS (p = 0.0007 and p = 0.0187, respectively). Beyond 3 years, segmental versus lobar Y90 was associated with improved OS with a median OS of 80.2 versus 46.7 months, respectively (p = 0.0024). Dosing > 200 Gy was not a significant predictor of improved OS. Conclusions: Super Survivors spanning the BCLC staging system maintained durable OS after radioembolization that was stratified by the extent of underlying liver disease. The common variable among all patients was an imaging response. Segmental versus lobar Y90 may have a long-term associated OS benefit.

AB - Purpose: To identify baseline characteristics and long-term prognostic factors in non-transplant patients with unresectable hepatocellular carcinoma (HCC) who had prolonged survival after treatment with yttrium-90 radioembolization (Y90). Materials and Methods: Sixty-seven “Super Survivors” (defined as ≥ 3-year survival after Y90) were identified within our 1000-patient Y90 database (2003–2017). Baseline imaging and follow-up occurred at 1 month and every 3 months thereafter. Overall survival (OS) was calculated with Kaplan–Meier estimates with log-rank test in subgroups: Child–Pugh (CP) score, distribution of disease, portal vein thrombus (PVT), and technique (segmental vs lobar Y90). Results: Median age 69.5 years (range 45–94 years); 69% male; 60% solitary HCC; 79% unilobar disease; 12% PVT; 10% ascites; Barcelona Clinic Liver Cancer Stage A—54%/B—28%/C—16%/D—2%; CP A—70%/B—28%/C—2%. Longest baseline tumor diameter was 5.4 ± 4.0 cm (mean ± SD). All patients had an imaging response (either partial or complete response). Median OS was 67.5 months (95% CI 55.2–82.5). CP score and main PVT stratified median OS (p = 0.0007 and p = 0.0187, respectively). Beyond 3 years, segmental versus lobar Y90 was associated with improved OS with a median OS of 80.2 versus 46.7 months, respectively (p = 0.0024). Dosing > 200 Gy was not a significant predictor of improved OS. Conclusions: Super Survivors spanning the BCLC staging system maintained durable OS after radioembolization that was stratified by the extent of underlying liver disease. The common variable among all patients was an imaging response. Segmental versus lobar Y90 may have a long-term associated OS benefit.

KW - Hepatocellular carcinoma

KW - Radioembolization

KW - Survival

KW - Yttrium-90

UR - http://www.scopus.com/inward/record.url?scp=85048363701&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048363701&partnerID=8YFLogxK

U2 - 10.1007/s00270-018-2008-y

DO - 10.1007/s00270-018-2008-y

M3 - Article

C2 - 29948005

AN - SCOPUS:85048363701

VL - 41

SP - 1557

EP - 1565

JO - CardioVascular and Interventional Radiology

JF - CardioVascular and Interventional Radiology

SN - 7415-5101

IS - 10

ER -